News | June 02, 2021
Progress on new ventures key for Aurobindo Pharma: ICICI Securities
Aurobindo has one of the most enduring generics ecosystems among peers
Aurobindo has one of the most enduring generics ecosystems among peers
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Adjusted PAT declined 18.8% YoY
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Subscribe To Our Newsletter & Stay Updated
